文献速递心律失常

心脏外科术后新发房颤的管理与结局:VISION 心脏外科队列

New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort.
PubMed 文献 · Eur Heart J · 2026-01-01

VISION心脏外科是一项覆盖12个国家的多中心前瞻性队列,纳入12 234例接受心脏手术的成人,旨在描述术后30天内新发房颤的发生率、治疗情况及其与术后1年结局的关系。结果显示31.8%的患者发生术后房颤,出院时抗栓与抗心律失常药物使用差异较大。术后房颤患者1年内临床房颤和全因死亡风险均显著升高。

要点

  • 心脏术后新发房颤发生率约三成,出院时抗凝和抗血小板使用差异大。
  • 术后房颤患者术后1年临床房颤检出风险显著高于无术后房颤者。
  • 术后房颤患者全因死亡风险增加,需要关注术后长期随访与管理。

核心结论

  • 心脏外科术后约三分之一的患者发生新发术后房颤,其抗栓和抗心律失常治疗存在较大差异。
  • 术后房颤患者在术后1年内临床房颤和全因死亡风险显著增加。

研究设计与样本

  • VISION心脏外科是一项在12个国家开展的前瞻性多中心队列研究。
  • 共纳入12 234例接受心脏手术的成人,其中55.3%为单纯冠状动脉旁路移植术。
  • 使用多变量Cox模型分析术后房颤与术后30天至1年结局的关联,并校正患者和手术特征及抗栓治疗。

主要发现

  • 术后30天内31.8%的患者发生术后房颤。
  • 术后房颤患者中,出院时15.6%仅接受抗凝治疗,54.3%仅接受抗血小板治疗,23.9%联用抗凝和抗血小板,6.3%两者均未使用。
  • 术后房颤患者中48.8%出院时正在使用胺碘酮。
  • 术后1年时,术后房颤患者临床房颤检出率为6.9%,无术后房颤者为0.6%。
  • 术后房颤患者卒中或血管性死亡复合结局发生率为2.3%,无术后房颤者为1.5%。

关键数值与推荐

  • 术后房颤患者1年临床房颤风险:校正风险比11.30,95%置信区间8.17-15.70。
  • 术后房颤患者卒中或血管性死亡复合结局:校正风险比1.32,95%置信区间0.99-1.77。
  • 术后房颤患者全因死亡:校正风险比1.54,95%置信区间1.18-2.00。

临床怎么用

  • 心脏术后新发房颤患者出院时抗栓治疗差异大,需结合卒中与出血风险进行个体化决策。
  • 术后房颤患者术后1年内应加强房颤筛查和全因死亡风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: New-onset atrial fibrillation (AF) is the most common complication of cardiac surgery. We aimed to describe the incidence of postoperative AF (POAF), its management, and its relationship to long-term outcomes in a prospective multi-centre cohort, as our current understanding comes primarily from registries and single-centre studies. METHODS: VISION Cardiac Surgery was a prospective cohort of adults who underwent cardiac surgery in 12 countries. The association of POAF with outcomes occurring between 30 days and 1 year postoperatively was estimated using a multivariable Cox model adjusted for patient and operative characteristics and for antithrombotic therapies. RESULTS: Among 12 234 patients (55.3% isolated coronary artery bypass grafting), 31.8% had POAF within 30 days of surgery. The proportion of participants with POAF who received anticoagulation alone at hospital discharge was 15.6%, 54.3% received antiplatelets alone, 23.9% received anticoagulation and antiplatelets, and 6.3% received neither; 48.8% were receiving amiodarone. At 1 year, clinical AF was detected in 6.9% of patients with POAF compared to 0.6% in those without [adjusted hazard ratio (aHR), 11.30; 95% confidence interval (CI) 8.17-15.70]. The primary composite outcome of stroke or vascular death occurred in 2.3% of patients with POAF and 1.5% in those without POAF (aHR 1.32; 95% CI 0.99-1.77). Patients with POAF had a higher risk of all-cause death (3.0% vs 1.7%; aHR 1.54; 95% CI 1.18-2.00). CONCLUSIONS: New-onset POAF occurs in a third of patients after cardiac surgery; its antithrombotic and antiarrhythmic management varies. Patients with POAF have increased risks of both clinical AF and of all-cause death in the year following surgery.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. McIntyre, Devereaux, Belley-Cote, et al. New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort. Eur Heart J. 2026. PMID: 41964448. doi:10.1093/eurheartj/ehag236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。